subject: Armodafinil - Key patent, SPC, and data exclusivity expiry (44 country coverage) [print this page] Armodafinil - Key patent, SPC, and data exclusivity expiry (44 country coverage)
Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.
This Pipeline Selector report covers Armodafinil
Armodafinil indications: Excessive sleepiness associated with narcolepsy; obstructive sleep apnea/hyponea syndrome; shift work sleep disorder
Armodafinil innovator: Cephalon (Nuvigil)
Examples of information found in this online report include:
# Includes key patent publications for 44 countries (see list below)
# Contains SPC protection for every EU state plus patent term extensions in other countries
# Data exclusivity calculated on a country by country basis
# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
# DMF & Paragraph IV filings
# Litigation alerts
# Marketing authorisation holders in selected territories
# Patent risk analysis via graphical display of data from patent filings
# Hyper-linking to crucial patent documents and national registries enabling data verification
The Key Patent Indicator enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. (also available with 44 country coverage)
